No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics Analyst Ratings
Innovative Cytokine Immunotherapy: Werewolf Therapeutics' Pioneering Approach and Promising Pipeline
Werewolf Therapeutics Advances Innovative Cytokine Therapies
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $13
Promising Potential of Werewolf Therapeutics' INDUKINE Platform Despite Challenges